The 33 novel fusions were identified in 21 patients involving RB1, BCL2, and BRCA2; none were identified in patients with TRS, and 21 (21.0%) were identified in patients with genomically complex and other sarcomas (p < 0.001). Here, RB1 is linked to sarcoma.